Guanfacine Tablet, Extended Release
Product Images NDC 46708-748

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 46708-748). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100 Tablets (Guanfacine 1)

Label for Guanfacine Extended-Release Tablets USP, 1 mg strength, oral tablet dosage form. The package contains 100 tablets and is labeled as prescription only. Manufactured by Alembic Pharmaceuticals Limited. The label includes storage instructions, a barcode, and NDC 46708-745-31.*

FDA Label Image

100 Tablets (Guanfacine 2)

Label for Guanfacine Extended-Release Tablets, USP, 2 mg strength, oral dosage form. The label indicates packaging of 100 tablets and states the manufacturer as Alembic Pharmaceuticals Limited. It includes storage instructions, a caution that tablets should not be crushed, and prescription-only status, along with the NDC number 46708-746-31.*

FDA Label Image

Figure2 (Guanfacine 2figure)

A chart displaying the pharmacokinetic fold change and 90% confidence intervals for guanfacine when co-administered with various CYP3A4/5 inhibitors, inducers, and other drugs. It shows changes in Cmax and AUC values relative to reference with human data and computer simulations, including ketoconazole, fluconazole, rifampin, efavirenz, oral methylphenidate, and lisdexamfetamine dimesylate.*

FDA Label Image

Figure 3 (Guanfacine 3 Figure)

A pharmacokinetic chart showing fold change and 90% confidence intervals for Cmax and AUC values of Oral Methylphenidate and Lisdexamfetamine Dimesylate as interacting drugs. The x-axis represents fold change relative to reference, ranging from 0 to 2, with points centered near 1 indicating minimal change.*

FDA Label Image

100 Tablets (Guanfacine 3)

Label for Guanfacine Extended-Release Tablets, USP, 3 mg strength, oral tablets. The package contains 100 tablets and is manufactured by Alembic Pharmaceuticals Limited. Storage instructions and dosage warnings are included, stating the tablets should not be crushed, chewed, or broken before swallowing. The label also displays the NDC 46708-747-31 and a barcode.*

FDA Label Image

100 Tablets (Guanfacine 4)

Label for Guanfacine Extended-Release Tablets, USP, 4 mg, oral dosage form. The label indicates 100 tablets per container, manufactured by Alembic Pharmaceuticals Limited. Storage instructions and a child-resistant package notice are included along with the NDC 46708-748-31.*

FDA Label Image

Figure1 (Guanfacine Figure 1)

A line graph comparing plasma concentration (ng/mL) over 24 hours of extended-release versus immediate-release Guanfacine, both at 1 mg once daily doses. The graph shows extended-release levels rising more gradually and maintaining steadier concentrations over time compared to a sharper peak followed by decline in immediate-release Guanfacine.*

FDA Label Image

Figure 4 (Guanfacine Figure4)

A line chart showing treatment failure percentage over time in days for Placebo and SPD503 groups. The x-axis represents time to treatment failure in days, ranging from 0 to over 200 days. The y-axis represents treatment failure percentage from 0% to 100%. The Placebo group shows higher treatment failure rates compared to SPD503 over the study duration.*

FDA Label Image

Structure (Guanfacine Str)

Chemical structure of guanfacine hydrochloride depicted with two chlorine atoms on the aromatic ring and the guanidine functional group, representing the active ingredient guanfacine as hydrochloride salt.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.